TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial

Abstract

Present data revealed higher event rates in patients who underwent everolimus-eluting bioresorbable scaffold (BRS) implantation compared with patients treated with metallic drug-eluting stents (DES). Of these studies, only 1 randomized trial is available, which addresses BRS use in patients with